{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-035068","form_type":"8-K","ticker":"TLSI","cik":"0001826667","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2026-05-14T20:03:27+00:00","discovered_at":"2026-05-14T20:04:00.237257+00:00","generated_at":"2026-05-14T20:05:13.183999+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"confidence":"high","headline":"TriSalus annual meeting elects two directors, ratifies auditor, approves say-on-pay frequency","bullets":["Mary Szela and Gary Gordon elected to three-year director terms with ~92% for votes.","Grant Thornton LLP ratified as independent auditor for fiscal 2026.","Advisory vote on exec compensation approved; board adopts three-year frequency for future votes.","Turnout: 67.9% of outstanding shares represented at the meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-035068","json":"https://secwatch.observer/filing/0001628280-26-035068.json","markdown":"https://secwatch.observer/filing/0001628280-26-035068.md","text":"https://secwatch.observer/filing/0001628280-26-035068.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826667/000162828026035068/0001628280-26-035068-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826667/000162828026035068/tlsi-20260514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T20:05:13.183999+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"257aa9939bcccc2ae201e50a56020691a13ef70c","claim":"TriSalus Life Sciences, Inc. shareholders approved Advisory vote on compensation of named executive officers at the 2026-05-14 meeting.","evidence_excerpt":"The proposal to approve, on an advisory basis, the compensation of the Company’s named executive officers was approved by the stockholder vote: For Against Abstain Broker Non-Votes 32,625,082 1,206,105 176,369 7,721,120","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826667/000162828026035068/0001628280-26-035068-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-05-14"}],"fact_type":"shareholder_vote"},{"claim_id":"3c22992d5bdb7dd8c67d0c1bcf26fd8d1f956dce","claim":"TriSalus Life Sciences, Inc. shareholders approved Ratification of appointment of Grant Thornton, LLP as independent registered accounting firm for the fiscal year ending December 31, 2026 at the 2026-05-14 meeting.","evidence_excerpt":"The appointment of Grant Thornton, LLP to serve as our independent registered accounting firm for the fiscal year ending December 31, 2026 was ratified by the stockholder vote: For Against Abstain 41,098,385 28,667 601,624","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826667/000162828026035068/0001628280-26-035068-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-05-14"}],"fact_type":"shareholder_vote"},{"claim_id":"bceeeca28d067c41b22815aa1364d2db882c0623","claim":"TriSalus Life Sciences, Inc. shareholders approved Advisory vote on frequency of future stockholder advisory votes on named executive officer compensation at the 2026-05-14 meeting.","evidence_excerpt":"The proposal to approve, on an advisory basis, a three-year frequency with which the Company should conduct future stockholder advisory votes on named executive officer compensation was approved by the stockholder vote: 1 Year 2 Years 3 Years Abstain Broker Non-Votes 12,656,430 736,931 20,348,386 265,809 7,721,120","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826667/000162828026035068/0001628280-26-035068-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay frequency"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-05-14"}],"fact_type":"shareholder_vote"},{"claim_id":"eb598dfe2978147a1bd9fc9b768377fddd9575a9","claim":"TriSalus Life Sciences, Inc. shareholders approved Election of Directors at the 2026-05-14 meeting.","evidence_excerpt":"The two nominees for Directors were elected to serve three-year terms to expire at the annual meeting of stockholders in 2029, as follows: Nominee For Withhold Broker Non-Votes Mary Szela 31,393,310 2,614,246 7,721,120 Gary Gordon 31,339,161 2,668,395 7,721,120","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826667/000162828026035068/0001628280-26-035068-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-05-14"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}